ArticleCNS neuroscience & therapeutics2023
Longitudinal cognitive changes in patients with early Parkinson's disease and neuropsychiatric symptoms.
Article in CNS neuroscience & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Neuropsychiatric symptoms and their impact on cognitive functioning in patients with parkinson's disease: A systematic review of the literature.Cognitive, affective & behavioral neuroscience · 2026Pooled it
- [Progress on prognostic assessment methods for mild cognitive impairment].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Review
- Prediction of impulse control disorders in Parkinson's disease through a longitudinal machine learning study.NPJ Parkinson's disease · 2026Article
- Comparison of clinical features and cerebral glucose metabolism between patients with major depressive disorder and Parkinson's with depression.BMC psychiatry · 2026Article
- Putative sympathetic-predominant subtype in body-first Parkinson's disease is associated with accelerated cognitive decline.Frontiers in aging neuroscience · 2026Article
- Neuropsychological aspects of impulse control disorders in Parkinson's disease.Frontiers in aging neuroscience · 2026Review
- Apathy in Parkinson's Disease: EEG Microstate Characteristics.Brain topography · 2025Article
- Prevalence, associated factors and impact of mild cognitive impairment in hospitalized older adults with Parkinson's disease: a cross-sectional study.Frontiers in aging neuroscience · 2025Article
- The impact of impulse control disorders on cognitive decline inFrontiers in neurology · 2025Article
- AI-assisted MRI segmentation analysis of brain region volume alterations in Parkinson's disease.Frontiers in human neuroscience · 2025Article
- Intermittent hypoxia exacerbates anxiety in high-fat diet-induced diabetic mice by inhibiting TREM2-regulated IFNAR1 signaling.Journal of neuroinflammation · 2024Article
- Synchronous monitoring of brain-heart electrophysiology using heart rate variability coupled with rapid quantitative electroencephalography in orthostatic hypotension patients with α-synucleinopathies: Rapid prediction of orthostatic hypotension and preliminary exploration of brain stimulation therapy.CNS neuroscience & therapeutics · 2024Article
- Mild Behavioral Impairment in Parkinson's Disease: An Updated Review on the Clinical, Genetic, Neuroanatomical, and Pathophysiological Aspects.Medicina (Kaunas, Lithuania) · 2024Review
- Mild cognitive impairment in Parkinson's disease: current view.Frontiers in cognition · 2024Review
- Longitudinal cognitive changes in patients with early Parkinson's disease and neuropsychiatric symptoms.CNS neuroscience & therapeutics · 2023Article
- Review
- Latent-profile analysis of sleep disturbances, cognitive performance and neuropsychiatric symptoms reveals subtypes of Parkinson's disease.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIn this study, we aimed to investigate the effect of neuropsychiatric symptoms (NPS) on the rate of cognitive decline for both global cognition and specific cognitive domains in a cohort of patients from the Parkinson's Progression Markers Initiative (PPMI).
methodProspectively longitudinal data were obtained from the PPMI cohort. NPS, including depression, anxiety, apathy, psychosis, impulse control disorders (ICDs), and cognition ability, were evaluated by a series of questionnaires. Linear mixed-effects models were used to investigate the relationship between NPS and the rate of cognitive decline. Generalized estimating equations (GEEs) were used to investigate the relationship between NPS and the occurrence of mild cognitive impairment (MCI).
resultsIn total, 423 patients with Parkinson's disease (PD) were recruited at baseline and 395, 378, 366, 346, and 315 participants were followed up at 1, 2, 3, 4, and 5 years, respectively. Depression, anxiety, apathy, and psychosis were associated with global cognitive decline. Except for those with ICDs, patients with psychosis, depression, anxiety, and apathy were more likely to meet the criteria for MCI. Patients with depression and anxiety showed a progressive decline in four major cognitive domains. Apathy and ICDs were separately associated with a progressive decline in processing speed-attention and memory, respectively.
conclusionsNeuropsychiatric symptoms, including psychosis, depression, anxiety, and apathy, could be used to predict future cognitive decline in patients with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.